Dr. Jurgen Schmitt was appointed as a scientific advisor of our Company in October 2016.  Dr. Schmitt brings over 20 years of experience in FT-IR and Raman spectoscropy research in microbiological and biomedical applications, as well as R&D and industrial applications in the diverse fields of Biotechnology, Medicine and Pharmaceutics.  Since 2000, he founded and acted as CEO of Synthon GmbH, a Company dedicated to the Development of Spectroscopic Applications in Medicine, Biotechnology and Pharmaceutical Research.  Synthon is based in Heidelberg, Germany.  Prior to that, Dr. Schmitt held scientific and academic positions at the University of Duisburg, Germany, Department of Aquatic Microbiology;  University of Stuttgart, Institute for Water Quality and Water Chemistry;  and Oak Ridge National Laboratory, US.


Mr. Moshe Schlisser was appointed as a director of our Company in February 2016. Mr. Schlisser holds managerial positions in investment firms with a focus on Venture Capital and Private Equity. Mr. Schlisser specializes in Strategic Partnerships, IPO and M&A transactions primarily for cutting edge technology companies. Mr. Schlisser also co-produced an international music awards show. As part of his philanthropy activities, Mr. Schlisser co-founded a soup kitchen that serves over 50 homeless and underprivileged individuals a hot prepared dinner every night and delivers weekend food packages to over 250 underprivileged families.


Mr. Moshe Abramovitz was appointed as a director of our Company in February 2016. Mr. Abramovitz has held managerial positions in various organizations (Israeli companies and charities) including acting as deputy CEO of A.S. Mehadrin Ltd. Mr. Abramovitz holds a B.A. in business administration, specializing in information system form Ono Academic College, Israel. Mr. Abramowitz received training and a certificate to serve a mediator from Bar Ilan University, Israel.


Mr. Asher Deutsch was appointed as a director of our Company in March 2016. Mr. Deutsch is a partner at the law firm of Asher Deutsch & Co. and has over 20 years of experience as a director on the boards of numerous private and public companies in Israel. Mr. Deutsch founded “Datshare business information Ltd.” in 1992, a company that develops and markets financial and marketing information systems to investors in capital markets for companies that are traded on the Tel Aviv stock exchange and Nasdaq. Mr. Deutsch also acts as an arbitrator in corporate and securities law related arbitrations. Mr. Deutsch was admitted to the Israeli bar association in 2008. Mr. Deutsch has a B.Sc. degree from Ben Gurion University, Israel and a law degree from Ono Academic College, Israel. Mr. Deutsch also studied business administration at Tel-Aviv University, Israel.

Michael C Little, PhD  — ADVISOR

During the last year, Michael has been Senior Vice President of R&D for Natera and President of Futura Partners, a healthcare advisory firm. At Futura, he advises clients from the pharma, life sciences and diagnostics industries in areas including diagnostics, companion diagnostics, and technical leadership development. He is a member of the Board of Directors of a Cambridge MA private startup company focused in personalized medicine (pulmonology), and has been a consultant to the investors and Board of Directors of another personalized medicine company (breast cancer).

Previously, he was Vice President and Global Head at Novartis. For the 1st 2 years, he oversaw R&D, medical affairs, and regulatory affairs for Novartis (Chiron) Diagnostics in Emeryville CA. When Novartis chose to build a new business unit focused on molecular and companion diagnostics within Pharma, he was selected to be one of the founding members to build a Diagnostics Development organization and processes from scratch in Cambridge MA. Over a period of 5 years he had responsibility for nearly 30 programs spanning Novartis’ entire oncology and general medicine portfolio.

Prior to Novartis, he was the Chief Operating Officer of Adlyfe, a venture-funded company in Rockville, focused on misfolded protein diagnostics. During this time he had accountability for both finance raising and R&D programs.

Michael spent 16 years with Becton Dickinson, where he began as an R&D scientist developing a proprietary nucleic acid amplification technology, Strand Displacement Amplification (SDA), and would ultimately run the business resulting from this initial research work. He assumed responsibility for and ran the R&D programs for BDs flagship SDA platforms, the BDProbeTecET and BDViper. After successfully completing the development in record time and gaining FDA clearance for the very 1st real-time DNA amplification system (beating the nearest competitor by 1 year), he assumed the leadership of the resulting molecular business. This business grew from 0-$100M within 5 years and achieved an aggregate of over $1B in revenue since.

His earlier career in biotech included a brief tenure at BioRad where he developed products for life science researchers, and at Baxter Dade, where he developed clinical immunoassay and coagulation products.
He received his PhD in Microbiology from the University of Florida and completed post-doctoral training at the University of Arizona in Tucson.

Contact Us


1 Hamada St. Rehovot 7670301 Israel


Contact Form


Name *

Email *

Company *

Phone *

Subject *

Message *